A number of Onglyza lawsuits have been filed across the country in recent years. Onglyza (saxagliptin) is one of a class of medications used to control diabetes. Collectively the drugs are known as DPP-4 inhibitors and they lower blood sugar by increasing insulin output and decreasing glucose excreted by the liver. In April 2016 the FDA warned of an increased risk of heart failure associated with Onglyza, and this remains the basis of the existing claims against manufacturers. Lawsuits had been filed by plaintiffs who claim a connection between Onglyza and pancreatitis and pancreatic cancer. However, the FDA has not found a causal link between DPP-4 medications and pancreatitis and pancreatic cancer, and those claims have been dismissed. The FDA does continue to study the relationship. Onglyza is manufactured by Bristol-Myers Squibb and AstraZeneca and the FDA approved its use in 2009.